307 related articles for article (PubMed ID: 8665909)
21. A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells.
Gutierrez LM; Viniegra S; Rueda J; Ferrer-Montiel AV; Canaves JM; Montal M
J Biol Chem; 1997 Jan; 272(5):2634-9. PubMed ID: 9006897
[TBL] [Abstract][Full Text] [Related]
22. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.
Blasi J; Chapman ER; Link E; Binz T; Yamasaki S; De Camilli P; Südhof TC; Niemann H; Jahn R
Nature; 1993 Sep; 365(6442):160-3. PubMed ID: 8103915
[TBL] [Abstract][Full Text] [Related]
23. Reductive chain separation of botulinum A toxin--a prerequisite to its inhibitory action on exocytosis in chromaffin cells.
Stecher B; Gratzl M; Ahnert-Hilger G
FEBS Lett; 1989 May; 248(1-2):23-7. PubMed ID: 2721679
[TBL] [Abstract][Full Text] [Related]
24. Modifications in the C terminus of the synaptosome-associated protein of 25 kDa (SNAP-25) and in the complementary region of synaptobrevin affect the final steps of exocytosis.
Gil A; Gutiérrez LM; Carrasco-Serrano C; Alonso MT; Viniegra S; Criado M
J Biol Chem; 2002 Mar; 277(12):9904-10. PubMed ID: 11786540
[TBL] [Abstract][Full Text] [Related]
25. The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking.
Ferrer-Montiel AV; Gutiérrez LM; Apland JP; Canaves JM; Gil A; Viniegra S; Biser JA; Adler M; Montal M
FEBS Lett; 1998 Sep; 435(1):84-8. PubMed ID: 9755864
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
[TBL] [Abstract][Full Text] [Related]
27. Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells.
Huang X; Wheeler MB; Kang YH; Sheu L; Lukacs GL; Trimble WS; Gaisano HY
Mol Endocrinol; 1998 Jul; 12(7):1060-70. PubMed ID: 9658409
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of synaptic neurotransmitter release mechanisms using bacterial toxins].
Doussau F; Humeau Y; Vitiello F; Popoff MR; Poulain B
J Soc Biol; 1999; 193(6):457-67. PubMed ID: 10783704
[TBL] [Abstract][Full Text] [Related]
29. Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis.
Washbourne P; Bortoletto N; Graham ME; Wilson MC; Burgoyne RD; Montecucco C
J Neurochem; 1999 Dec; 73(6):2424-33. PubMed ID: 10582602
[TBL] [Abstract][Full Text] [Related]
30. Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis.
Koticha DK; McCarthy EE; Baldini G
J Cell Sci; 2002 Aug; 115(Pt 16):3341-51. PubMed ID: 12140265
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25.
Apland JP; Adler M; Oyler GA
J Protein Chem; 2003 Feb; 22(2):147-53. PubMed ID: 12760419
[TBL] [Abstract][Full Text] [Related]
32. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage.
Sakaba T; Stein A; Jahn R; Neher E
Science; 2005 Jul; 309(5733):491-4. PubMed ID: 16020741
[TBL] [Abstract][Full Text] [Related]
33. Isolated light chains of botulinum neurotoxins inhibit exocytosis. Studies in digitonin-permeabilized chromaffin cells.
Bittner MA; DasGupta BR; Holz RW
J Biol Chem; 1989 Jun; 264(18):10354-60. PubMed ID: 2732226
[TBL] [Abstract][Full Text] [Related]
34. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin.
Yamasaki S; Baumeister A; Binz T; Blasi J; Link E; Cornille F; Roques B; Fykse EM; Südhof TC; Jahn R
J Biol Chem; 1994 Apr; 269(17):12764-72. PubMed ID: 8175689
[TBL] [Abstract][Full Text] [Related]
35. SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion.
Sadoul K; Berger A; Niemann H; Weller U; Roche PA; Klip A; Trimble WS; Regazzi R; Catsicas S; Halban PA
J Biol Chem; 1997 Dec; 272(52):33023-7. PubMed ID: 9407084
[TBL] [Abstract][Full Text] [Related]
36. The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes.
Gerona RR; Larsen EC; Kowalchyk JA; Martin TF
J Biol Chem; 2000 Mar; 275(9):6328-36. PubMed ID: 10692432
[TBL] [Abstract][Full Text] [Related]
37. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.
Keller JE; Neale EA
J Biol Chem; 2001 Apr; 276(16):13476-82. PubMed ID: 11278807
[TBL] [Abstract][Full Text] [Related]
38. Ca(2+) influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis.
Huang X; Kang YH; Pasyk EA; Sheu L; Wheeler MB; Trimble WS; Salapatek A; Gaisano HY
Am J Physiol Cell Physiol; 2001 Sep; 281(3):C740-50. PubMed ID: 11502551
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.
Lawrence GW; Ovsepian SV; Wang J; Aoki KR; Dolly JO
Neuropharmacology; 2013 Jul; 70():287-95. PubMed ID: 23485402
[TBL] [Abstract][Full Text] [Related]
40. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis.
Washbourne P; Pellizzari R; Baldini G; Wilson MC; Montecucco C
FEBS Lett; 1997 Nov; 418(1-2):1-5. PubMed ID: 9414082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
